Head-to-head comparison of Retatrutide and Tirzepatide for fat loss. Which triple vs dual agonist produces better results?
Retatrutide and Tirzepatide are both next-generation weight loss peptides, but Retatrutide adds a third receptor target — the glucagon receptor — on top of the GIP and GLP-1 targets shared with Tirzepatide. This makes Retatrutide the most potent fat loss peptide in clinical trials, but also the most aggressive in terms of side effects.
Our Verdict
Winner: Retatrutide (fat loss) / Tirzepatide (tolerability)
Retatrutide wins on fat loss — up to 24% body weight reduction vs 15–22% for Tirzepatide in clinical trials. Tirzepatide wins on tolerability and established safety data. For researchers prioritizing maximum fat loss and willing to manage more aggressive titration, Retatrutide is the stronger compound. For those wanting proven results with a more established safety profile, Tirzepatide is the better choice.
| Category | Retatrutide | Tirzepatide |
|---|---|---|
| Receptor Targets | GIP + GLP-1 + Glucagon (triple agonist) | GIP + GLP-1 (dual agonist) |
| Fat Loss (Clinical) | Up to 24% body weight at 48 weeks | 15–22% body weight at 72 weeks |
| Side Effects | More intense GI effects, especially early | Moderate GI effects, well-characterized |
| Half-life | ~6 days (once weekly) | ~5 days (once weekly) |
| Starting Dose | 0.5–1mg/week | 2.5mg/week |
| FDA Approval | Phase 3 trials (not yet approved) | Approved (Mounjaro/Zepbound) |
| Safety Data | Limited long-term data | Extensive clinical trial data |
| Best For | Maximum fat loss, aggressive protocols | Proven fat loss with established safety |
Purgo Labs carries pharmaceutical-grade Retatrutide and Tirzepatide with third-party COAs. Use code HEALTH for 15% off.
Yes — Retatrutide produces greater fat loss (up to 24% vs 15–22%) due to the added glucagon receptor agonism, which directly promotes lipolysis beyond what GLP-1 alone achieves.
Yes, but always restart titration from the lowest dose. Receptor sensitivity does not carry over between compounds — starting Retatrutide at an equivalent Tirzepatide dose will cause significant GI side effects.
Retatrutide tends to have more intense early GI side effects (nausea, vomiting) due to the glucagon component. Slow titration starting at 0.5–1mg/week minimizes this significantly.
Use our free peptide calculator to convert your dose into exact syringe units based on your vial concentration.
Purgo Labs provides pharmaceutical-grade research peptides with third-party COAs. Use code HEALTH for 15% off your first order.
Visit Purgo LabsMedical Disclaimer: All content on this site is for educational and research purposes only. Research peptides are not FDA-approved for human use. Always consult a qualified healthcare professional before considering any peptide or supplement protocol. Nothing on this site constitutes medical advice, diagnosis, or treatment.